Ascentage Pharma announced promising results from a Phase Ib study on olverembatinib for patients with SDH-deficient GIST, a rare tumor type. The study showed an ORR of 23.1%, CBR of 84.6%, and mPFS of 25.7 months in 26 patients. Olverembatinib was well tolerated, with a median follow-up of 14.5 months. The drug targets lipid metabolism and inhibits tumorigenic signaling pathways, offering a potential treatment option for this patient population. A Phase III study is ongoing to further evaluate olverembatinib’s efficacy and safety.

Gastrointestinal stromal tumors are rare, affecting 10-15 cases per million annually. SDH-deficient GIST, accounting for 5-7.5% of cases, lacks effective treatments. Olverembatinib, a third-generation BCR::ABL1 inhibitor, shows promise in addressing this unmet clinical need. The drug is being evaluated in a Phase III study for patients with SDH-deficient GIST, with Breakthrough Therapy Designation in China. Olverembatinib targets lipid metabolism and tumorigenic pathways, offering a potential breakthrough in treating this rare condition.

Read more at GlobeNewswire: Ascentage Pharma Announces Publication of Olverembatinib